{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:14:55Z","timestamp":1787238895491,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.alit.2021.08.005","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T18:48:55Z","timestamp":1630176535000},"page":"163-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Drug-induced scleroderma-like lesion"],"prefix":"10.1016","volume":"71","author":[{"given":"Yasuhito","family":"Hamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2021.08.005_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0738-081X(98)00006-6","article-title":"Drug-induced scleroderma and sclerodermiform conditions","volume":"16","author":"Haustein","year":"1998","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/00002281-200301000-00013","article-title":"Drug-induced rheumatic syndromes","volume":"15","author":"Brogan","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-induced lupus: traditional and new concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.alit.2021.08.005_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.alit.2021.08.005_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0190-9622(80)80292-1","article-title":"Skin manifestations of pentazocine abuse","volume":"2","author":"Palestine","year":"1980","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0304-4165(80)90309-8","article-title":"Bleomycin-induced synthesis of type I procollagen by human lung and skin fibroblasts in culture","volume":"631","author":"Clark","year":"1980","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.alit.2021.08.005_bib7","first-page":"651","article-title":"Bleomycin-induced scleroderma","volume":"7","author":"Finch","year":"1980","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/1346-8138.13156","article-title":"Biomarkers in systemic sclerosis: their potential to predict clinical courses","volume":"43","author":"Hasegawa","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.bjc.6600347","article-title":"Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes","volume":"87","author":"Tsavaris","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.alit.2021.08.005_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjd.13899","article-title":"Glycosaminoglycan and versican deposits in taxane-induced sclerosis","volume":"173","author":"Okada","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2010.06.008","article-title":"The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis","volume":"59","author":"Asano","year":"2010","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.alit.2021.08.005_bib12","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/j.1365-2133.2011.10243.x","article-title":"A\u00a0case of taxane-induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis","volume":"164","author":"Takahashi","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/exd.12500","article-title":"Role of endothelin-1\/endothelin receptor signaling in fibrosis and calcification in nephrogenic systemic fibrosis","volume":"23","author":"Motegi","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib14","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib15","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1078::AID-CNCR19>3.0.CO;2-T","article-title":"Cutaneous fibrosis induced by docetaxel: a case report","volume":"88","author":"Cleveland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.alit.2021.08.005_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/ijd.12437","article-title":"Paclitaxel-induced diffuse cutaneous sclerosis: a case with associated esophageal dysmotility, Raynaud's phenomenon, and myositis","volume":"55","author":"Winkelmann","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archderm.1973.01620190029007","article-title":"Cutaneous toxicity of bleomycin therapy","volume":"107","author":"Cohen","year":"1973","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib18","first-page":"294","article-title":"Scleroderma in association with the use of bleomycin: a report of 3 cases","volume":"19","author":"Kerr","year":"1992","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1346-8138.2011.01301.x","article-title":"Case of bleomycin-induced scleroderma","volume":"39","author":"Inaoki","year":"2012","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/1097-0142(19950701)76:1<110::AID-CNCR2820760117>3.0.CO;2-9","article-title":"Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases","volume":"76","author":"Battafarano","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.alit.2021.08.005_bib21","first-page":"1037","article-title":"Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion","volume":"53","author":"Extra","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.alit.2021.08.005_bib22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2230.2004.01519.x","article-title":"Scleroderma and the taxanes. Is there really a link?","volume":"29","author":"Farrant","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2133.2006.07597.x","article-title":"Taxane-induced scleroderma","volume":"156","author":"Itoh","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2230.2004.01668.x","article-title":"Chemotherapy-induced scleroderma: a pleiomorphic syndrome","volume":"30","author":"Alexandrescu","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib25","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaad.2001.07.001","article-title":"Gemcitabine-associated scleroderma-like changes of the lower extremities","volume":"51","author":"Bessis","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/000155501317208381","article-title":"Gemcitabine-induced acute lipodermatosclerosis-like reaction","volume":"81","author":"Chu","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2021.08.005_bib27","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/ijd.14067","article-title":"Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature","volume":"57","author":"Verhulst","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib28","first-page":"769","article-title":"Revisiting cutaneous adverse reactions to pemetrexed","volume":"2","author":"Pierard-Franchimont","year":"2011","journal-title":"Oncol Lett"},{"key":"10.1016\/j.alit.2021.08.005_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clon.2012.01.003","article-title":"Pemetrexed-induced skin sclerosis","volume":"24","author":"Merklen-Djafri","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.alit.2021.08.005_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.annder.2014.11.011","article-title":"[Pemetrexed-induced scleroderma-like changes in the lower legs]","volume":"142","author":"Corbaux","year":"2015","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.alit.2021.08.005_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/1346-8138.13354","article-title":"Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma","volume":"43","author":"Ishikawa","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.alit.2021.08.005_bib33","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1111\/1346-8138.14492","article-title":"Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma","volume":"46","author":"Cho","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib34","first-page":"701","article-title":"Nivolumab induced morphea","volume":"155","author":"Dal Bello","year":"2020","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.alit.2021.08.005_bib35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ad.2016.07.013","article-title":"Relapse of morphea during Nivolumab therapy for lung adenocarcinoma","volume":"108","author":"Alegre-Sanchez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.alit.2021.08.005_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/annonc\/mdw543","article-title":"Pembrolizumab induced severe sclerodermoid reaction","volume":"28","author":"Shenoy","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.alit.2021.08.005_bib37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by Pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.alit.2021.08.005_bib38","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/ijd.14097","article-title":"Generalized morphea in the setting of pembrolizumab","volume":"58","author":"Cheng","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib39","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.018","article-title":"Generalised morphea induced by pembrolizumab","volume":"116","author":"Herrscher","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.alit.2021.08.005_bib40","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.alit.2021.08.005_bib41","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2021.08.005_bib42","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1002\/art.22925","article-title":"Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure","volume":"56","author":"Todd","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.alit.2021.08.005_bib43","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A\u00a0systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.alit.2021.08.005_bib44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2133.2005.06708.x","article-title":"Methysergide-induced scleroderma-like changes of the legs","volume":"153","author":"Kluger","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00296-018-4227-6","article-title":"Systemic sclerosis induced by the use of cocaine: is there an association?","volume":"39","author":"Andreussi","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.alit.2021.08.005_bib46","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0190-9622(00)90233-0","article-title":"Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent","volume":"42","author":"Kono","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib47","first-page":"210","article-title":"Pentazocine induced myocutaneous sclerosis","volume":"13","author":"Hertzman","year":"1986","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0190-9622(08)81051-1","article-title":"Parenteral pentazocine: cutaneous complications revisited","volume":"22","author":"Furner","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-4362.1989.tb02457.x","article-title":"Morphea after bromocriptine therapy","volume":"28","author":"Leshin","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib50","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(82)91895-5","article-title":"Bromocriptine induced collagenosis-like symptomatology in Parkinson's disease","volume":"1","author":"Dupont","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2021.08.005_bib51","first-page":"162","article-title":"[Skin lesions after injection abuse. Chronic changes caused by ketobemidone (Ketogan)]","volume":"156","author":"Danielsen","year":"1994","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.alit.2021.08.005_bib52","first-page":"765","article-title":"Eosinophilia-myalgia syndrome--New Mexico","volume":"38","author":"Centers for Disease","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.alit.2021.08.005_bib53","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199008093230601","article-title":"An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use","volume":"323","author":"Belongia","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.alit.2021.08.005_bib54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2133.1993.tb00241.x","article-title":"Scleroderma and autoimmune thrombocytopenia associated with ingestion of L-tryptophan","volume":"128","author":"Morgan","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib55","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1038\/jid.1993.31","article-title":"L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis","volume":"100","author":"Varga","year":"1993","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib56","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0190-9622(08)80475-6","article-title":"Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa","volume":"25","author":"Joly","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib57","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/0028-3886.173656","article-title":"Carbidopa-induced eosinophilic fasciitis: a review","volume":"64","author":"Esteban-Fernandez","year":"2016","journal-title":"Neurol India"},{"key":"10.1016\/j.alit.2021.08.005_bib58","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/adc.50.8.658","article-title":"Lupus-scleroderma syndrome induced by ethosuximide","volume":"50","author":"Teoh","year":"1975","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.alit.2021.08.005_bib59","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1684\/ejd.2016.2942","article-title":"Ethosuximide-induced lupus-scleroderma syndrome with disease-specific autoantibodies","volume":"27","author":"Toyama","year":"2017","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib60","first-page":"254","article-title":"Systemic sclerosis after therapy with appetite suppressants","volume":"11","author":"Tomlinson","year":"1984","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/03009749009092627","article-title":"Scleroderma after therapy with appetite suppressants. Report on four cases","volume":"19","author":"Aeschlimann","year":"1990","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(83)91578-7","article-title":"Genetic susceptibility to scleroderma-like syndrome induced by vinyl chloride","volume":"1","author":"Black","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2021.08.005_bib63","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2230.1992.tb00210.x","article-title":"Atypical systemic sclerosis following exposure to vinyl chloride monomer. A case report and review of the cutaneous aspects of vinyl chloride disease","volume":"17","author":"Ostlere","year":"1992","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib64","first-page":"363","article-title":"[Scleroderma-like hypodermitis of the buttock due to intramuscular injection of drugs combined with vitamin K1]","volume":"99","author":"Texier","year":"1972","journal-title":"Ann Dermatol Syphiligr (Paris)"},{"key":"10.1016\/j.alit.2021.08.005_bib65","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0190-9622(88)70225-X","article-title":"Cutaneous reactions to vitamin K","volume":"19","author":"Sanders","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-4362.1995.tb01569.x","article-title":"Morphea-like reaction from vitamin K1","volume":"34","author":"Morell","year":"1995","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2133.1987.tb05795.x","article-title":"Systemic sclerosis-like lesions during long-term penicillamine therapy for Wilson's disease","volume":"116","author":"Miyagawa","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib68","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/ard.48.11.963","article-title":"Development of morphoea in rheumatoid arthritis treated with penicillamine","volume":"48","author":"Liddle","year":"1989","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2021.08.005_bib69","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1346-8138.1992.tb03814.x","article-title":"Nodular scleroderma in systemic sclerosis under D-penicillamine therapy","volume":"19","author":"Sasaki","year":"1992","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.alit.2021.08.005_bib70","first-page":"1242","article-title":"Scleroderma and eosinophilic fasciitis in patients taking fosinopril","volume":"24","author":"Biasi","year":"1997","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.alit.2021.08.005_bib71","first-page":"353","article-title":"[Sclerodermiform linear atrophy caused by triamcinolone]","volume":"13","author":"Rodriguez Prieto","year":"1985","journal-title":"Med Cutan Ibero Lat Am"},{"key":"10.1016\/j.alit.2021.08.005_bib72","first-page":"263","article-title":"Systemic sclerosis induced by interferon-alfa treatment of melanoma","volume":"42","author":"Silva","year":"2017","journal-title":"Acta Reumatol Port"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893021000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893021000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:11:59Z","timestamp":1761156719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893021000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1323893021000939"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2021.08.005","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced scleroderma-like lesion","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2021.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}